810 related articles for article (PubMed ID: 33690091)
21. Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statement.
Navani N; Butler R; Ibrahimo S; Verma A; Evans M; Doherty GJ; Ahmed S
Lung Cancer; 2022 Oct; 172():142-153. PubMed ID: 36099709
[TBL] [Abstract][Full Text] [Related]
22. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
[TBL] [Abstract][Full Text] [Related]
23. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
24. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.
Volckmar AL; Leichsenring J; Kirchner M; Christopoulos P; Neumann O; Budczies J; Morais de Oliveira CM; Rempel E; Buchhalter I; Brandt R; Allgäuer M; Talla SB; von Winterfeld M; Herpel E; Goeppert B; Lier A; Winter H; Brummer T; Fröhling S; Faehling M; Fischer JR; Heußel CP; Herth F; Lasitschka F; Schirmacher P; Thomas M; Endris V; Penzel R; Stenzinger A
Int J Cancer; 2019 Aug; 145(3):649-661. PubMed ID: 30653256
[TBL] [Abstract][Full Text] [Related]
25. Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay.
Hou H; Yang X; Zhang J; Zhang Z; Xu X; Zhang X; Zhang C; Liu D; Yan W; Zhou N; Zhu H; Qian Z; Li Z; Zhang X
Sci Rep; 2017 Nov; 7(1):14605. PubMed ID: 29097733
[TBL] [Abstract][Full Text] [Related]
26. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Garrido P; Conde E; de Castro J; Gómez-Román JJ; Felip E; Pijuan L; Isla D; Sanz J; Paz-Ares L; López-Ríos F
Clin Transl Oncol; 2020 Jul; 22(7):989-1003. PubMed ID: 31598903
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review.
Zheng Y; Vioix H; Liu FX; Singh B; Sharma S; Sharda D
Future Oncol; 2022 Feb; 18(4):505-518. PubMed ID: 34865516
[TBL] [Abstract][Full Text] [Related]
28. The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.
Fumagalli C; Vacirca D; Rappa A; Passaro A; Guarize J; Rafaniello Raviele P; de Marinis F; Spaggiari L; Casadio C; Viale G; Barberis M; Guerini-Rocco E
J Clin Pathol; 2018 Sep; 71(9):767-773. PubMed ID: 29535211
[TBL] [Abstract][Full Text] [Related]
29. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
30. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
[TBL] [Abstract][Full Text] [Related]
31. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.
Lee DH
Pharmacol Ther; 2017 Jun; 174():1-21. PubMed ID: 28167215
[TBL] [Abstract][Full Text] [Related]
32. Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe.
Hofman P; Calabrese F; Kern I; Adam J; Alarcão A; Alborelli I; Anton NT; Arndt A; Avdalyan A; Barberis M; Bégueret H; Bisig B; Blons H; Boström P; Brcic L; Bubanovic G; Buisson A; Caliò A; Cannone M; Carvalho L; Caumont C; Cayre A; Chalabreysse L; Chenard MP; Conde E; Copin MC; Côté JF; D'Haene N; Dai HY; de Leval L; Delongova P; Denčić-Fekete M; Fabre A; Ferenc F; Forest F; de Fraipont F; Garcia-Martos M; Gauchotte G; Geraghty R; Guerin E; Guerrero D; Hernandez S; Hurník P; Jean-Jacques B; Kashofer K; Kazdal D; Lantuejoul S; Leonce C; Lupo A; Malapelle U; Matej R; Merlin JL; Mertz KD; Morel A; Mutka A; Normanno N; Ovidiu P; Panizo A; Papotti MG; Parobkova E; Pasello G; Pauwels P; Pelosi G; Penault-Llorca F; Picot T; Piton N; Pittaro A; Planchard G; Poté N; Radonic T; Rapa I; Rappa A; Roma C; Rot M; Sabourin JC; Salmon I; Prince SS; Scarpa A; Schuuring E; Serre I; Siozopoulou V; Sizaret D; Smojver-Ježek S; Solassol J; Steinestel K; Stojšić J; Syrykh C; Timofeev S; Troncone G; Uguen A; Valmary-Degano S; Vigier A; Volante M; Wahl SGF; Stenzinger A; Ilié M
ESMO Open; 2023 Oct; 8(5):101628. PubMed ID: 37713929
[TBL] [Abstract][Full Text] [Related]
33. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
[TBL] [Abstract][Full Text] [Related]
34. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
Pirker R; Herth FJ; Kerr KM; Filipits M; Taron M; Gandara D; Hirsch FR; Grunenwald D; Popper H; Smit E; Dietel M; Marchetti A; Manegold C; Schirmacher P; Thomas M; Rosell R; Cappuzzo F; Stahel R;
J Thorac Oncol; 2010 Oct; 5(10):1706-13. PubMed ID: 20871269
[TBL] [Abstract][Full Text] [Related]
35. The Importance of Biomarker Testing in the Treatment of Advanced Non-Small Cell Lung Cancer: A Podcast.
Hirsch FR; Kim C
Oncol Ther; 2024 Jun; 12(2):223-231. PubMed ID: 38536631
[TBL] [Abstract][Full Text] [Related]
36. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
[TBL] [Abstract][Full Text] [Related]
37. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
38. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
39. NSCLC: An Update of Driver Mutations, Their Role in Pathogenesis and Clinical Significance.
Black RC; Khurshid H
R I Med J (2013); 2015 Oct; 98(10):25-8. PubMed ID: 26422542
[TBL] [Abstract][Full Text] [Related]
40. Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice.
Moore DA; Balbi K; Ingham A; Arkenau HT; Bennett P
J Clin Pathol; 2018 Nov; 71(11):1001-1006. PubMed ID: 30054375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]